New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1589-1596

  Ceriello, Antonio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FP 15; HEXOSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXYNITRITE; POLYOL; PROPIONYLCARNITINE; PROTEIN KINASE C; RUBOXISTAURIN; SUPEROXIDE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CLINICAL PATHWAY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DNA DAMAGE; DRUG MECHANISM; ELECTRON TRANSPORT; ENDOTHELIUM LESION; ENZYME ACTIVATION; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; OXIDATIVE STRESS; PATHOGENESIS; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DNA DAMAGE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PEROXYNITROUS ACID;

EID: 0042093769     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1589     Document Type: Review

References (96)

1. Kannel WB, McGee DL: Diabetes and cardiovascular diseases: the Framingham Study. JAMA 241:2035-2038, 1979
2. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. The Diabetes Control and Complications Trials (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937-942, 1999
5. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974, 2000
6. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
7. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 87:840-844, 2000
8. Marchioli R, Schweiger C, Levantesi G, Gavazzi L, Valagussa F: Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36:S53-S63, 2001
9. Meraji S, Jayakody L, Senaratne PJ, Thomson ABR, Kappagoda T: Endothelium-dependent relaxation in aorta of BB rat, Diabetes 36:978-981, 1987
10. Mayhan WG: Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am J Physiol 256:H621-H625, 1989
11. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88:2510-2516, 1993
12. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 35:771-776, 1992
13. Bohlen HG, Lash JM: Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilatation of normal rat arterioles. Am J Physiol 265:H219-H225, 1993
14. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783-1790, 1997
15. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
16. Tesfamariam B, Cohen RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 263:H321-H326, 1992
17. Diederich D, Skopec J, Diederich A, Dai F: Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 266:H1153-H1161, 1994
18. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D: Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 268:E1167-E1173, 1995
19. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22-28, 1996
20. Ceriello A, Motz E, Giugliano D: Vitamin C and hypertension. Lancet 355:1271-1272, 2000
21. Beckman JA, Goldfine AB, Gordon MB, Creager MA: Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103:1618-1623, 2001
22. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
23. Nishikawa T, Edelstein D, Du X-L, Yamagishi S, Matsumura T, Kaneda Y, Yorek M, Beebe D, Oates P, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
24. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the exosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97:12222-12226, 2002
25. Cross A,Jones O: Enzymic mechanisms of superoxide production. Biochim Biophys Acta 1057:281-198, 1991
26. Collins T: Endothelial nuclear factor kB and the initiation of the atherosclerotic lesion. Lab Invest 68:499-508, 1993
27. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142, 1991
28. Nathan C, Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 78:915-918, 1994
29. Baox KJ, Thiel BA, Stuehr DJ: Macrophage nitric oxide synthase subunits. J Biol Chem 268:21120-21129, 1993
30. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348, 2001
31. Benz D, Cadet P, Mantione K, Zhu W, Stefano GB: Tonal nitric oxide and health: a free radical and scavenger of free radicals. Med Sci Monit 8:RA1-RA4, 2002
32. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RAK, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:14-22, 2001
33. Spitaler MM, Graier WF: Vascular targets of redox signalling in diabetes mellitus. Diabetologia 45:476-494, 2002
34. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-C1437, 1996
35. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatuga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-1662, 2002
36. Brodsky SV, Gao S, Li H, Goligorsky MS: Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol 283: H2130-H2139, 2002
37. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96:25-28, 1997
38. Zou MH, Shi C, Cohen RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109:817-826, 2002
39. Ischiropoulos H: Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species, Arch Biochem Biophys 356:1-11, 1998
40. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44:834-838, 2001
41. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak C, Heinecke JW: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107:853-860, 2001
42. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects (Letter). J Clin Invest 108:635-636, 2001
43. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E: The role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25:1439-1443, 2002
44. Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Martella R, Nappo F, Berrino L, Rossi F, Giugliano D: Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51:1076-1082, 2002
45. Mihm MJ, Jing L, Bauer JA: Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 36:182-187, 2000
46. Frustaci A, Kajstura J, Cimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P: Myocardial cell death in human diabetes. Circ Res 87:1123-1132, 2000
47. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Cimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P: IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50:1414-1424, 2001
48. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113, 2001
49. Garcia Soriano F, Virag L, Szabo C: Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 79:437-448, 2001
50. Park KS, Kim JH, Kim MS, Kim JM, Kim SK, Choi JY, Chung MH, Han B, Kim SY, Lee HK: Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes 50:2837-2841, 2001
51. Kamoshima W, Kitamura Y, Nomura Y, Taniguchi T: Possible involvement of ADP-ribosylation of particular enzymes in cell death induced by nitric oxide-donors in human neuroblastoma cells. Neurochem Int 30:305-311, 1997
52. Garcia Soriano F, Pacher P, Mabley JG, Liaudet L, Szabo E, Szabo C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase activation. Circ Res 89:684-691, 2001
53. Pacher P, Liaudet L, Garcia Soriano F, Mabley JG, Szabo E, Szabo C: The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514-521, 2002
54. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Reviews 53:135-159, 2001
55. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A: Effects of the superoxide dismutase mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 436:111-118, 2002
56. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Salvemini D, Yorek MA: Effect of M40403 treatment of diabetic rats on endoneurial blood Row, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 134:21-29, 2001
57. Packer L, Valenza M, Serbinova E, Starke-Reed P, Frost K, Kagan V: Free radical scavenging is involved in the protective affect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart. Arch Biochem Biophys 288:533-537, 1991
58. Broderick TL, Haloftis G, Paulson DJ: L-propionyl-carnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. J Mol Cell Cardiol 2:331-340, 1996
59. Vanella A, Russo A, Acquaviva R, Campisi A, Di Giacomo Sorrenti V, Barcellona ML: L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol 16:99-104, 2000
60. Felix C, Gillis M, Driedzic WR, Paulson DJ, Broderick TL: Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart. Diabetes Res Clin Pract 53:17-24, 2001
61. Cotter MA, Cameron NE, Keegan A, Dines KC: Effects of acetyl and propionyl-L-carnitine on peripheral nerve function and vascular supply in experimental diabetes. Metabolism 44:1209-1214, 1995
62. Packer L, Kraemer K, Rimbach G: Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17:888-895, 2001
63. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50:1927-1937, 2001
64. Hetizer T, Finckh B, Albers S, Krohn K, Kohlschutter A, Meinertz T: Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 31:53-61, 2001
65. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA: Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107-111, 2002
66. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman, Groves JT: Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: Studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571-580, 2002
67. Kowluru RA: Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 38:179-185, 2001
68. Zingarelli B, Salzman AL, Szabo C: Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 13:85-94, 1998
69. Szabo C, Virag L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, Zingarelli B, Salzman A, Kun E: Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci U S A 95:3867-3872, 1998
70. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G: Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-I deficient mice. EMBO J 18:4446-4454,1999
71. Virag L, Salzman AL, Szabo C: Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 161:3753-3759, 1998
72. Li M, Pascual G, Glass CK: Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20:4699-4707, 2000
73. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719, 2001
74. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, Lerebours G, Thuillez C: Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 102:351-356, 2000
75. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215-222, 1999
76. Wassmann S, Baumer AT, Strehlow K, van Eickels M, Grohe C, Ahlbory K, Rosen R, Bohm M, Nickenig G: Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 103:435-441, 2001
77. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, Kadowaki T, Mayumi T, Yura Y, Kamisaki Y: PPAR-gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 448:231-238, 2002
78. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T: Statin-stimulated nitric oxide release from endothelium. Med Sci Monit 7:622-627, 2001
79. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M: Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51:2648-2652, 2002
80. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A: Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379, 2001
81. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
82. Sen K, Misra A, Kumar A, Pandey RM: Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 56:1-11, 2002
83. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
84. Takemoto M, Node K, Nakagami H, Liao Y, Grimm, M, Takemoto Y, Kitakaze M, Liao JK: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108:1429-1437, 2001
85. Münzel T, Keaney JF: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 104:1571-1574, 2001
86. Nickenig G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation 105:393-396, 2002
87. Gabrieiy I, Yang XM, Cases JA, Ma XH, Rossettt L, Barzilai N: Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol 281:R795-R802, 2001
88. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351:28-31, 1998
89. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
90. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
91. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
92. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. N Engl J Med 345:870-878, 2001
93. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U; Fyhrquist F,Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010, 2002
94. Ceriello A, Motz E: Angiotensin-receptor blockers, type 2 diabetes, and renoprotection (Letter). N Engl J Med 346:705-707, 2002
95. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61:186-194, 2002
96. Ceriello A, Morocutti A, Mercuri L, Quagliaro L, Moro M, Damante G, Viberti GC: Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 49:2170-2177, 2000